Lizinopril H Mibe 10 mg/12,5 mg tablete
| Name | Lizinopril H Mibe 10 mg/12,5 mg tablete |
|---|---|
| Former Name | Lizinopril H Farmal 10 mg/12,5 mg tablete |
| Marketing Authorisation Number | HR-H-493698039 |
| Active Substance | lizinopril dihidrat hidroklorotiazid |
| Composition | jedna tableta sadrži 10 mg lizinoprila u obliku lizinopril dihidrata i 12,5 mg hidroklorotiazida |
| Pharmaceutical Form | tableta |
| Manufacturer | mibe GmbH Arzneimittel, Brehna, Njemačka |
| Marketing Authorisation Holder | Mibe Pharmaceuticals d.o.o., Zavrtnica 17, Zagreb, Hrvatska |
| Marketing Authorisation Date | 31.01.2020 |
| MA Period of Validity | unlimited |
| Classification Number | UP/I-530-09/15-02/254 |
| Registration Number | 381-12-01/30-20-27 |
| Prescription | Medicinal product subject to medical prescription |
| Type of prescription | ponovljivi recept |
| Distribution | Supply through pharmacies (community) |
| Advertising to general public | not allowed |
| ATC Code | C09BA03 |
| Marketing status | stavljeno u promet |
| Shortage status | nema nestašice |
| SmPC | download |
| PL | download |
Packaging
Direct Healthcare Professional Communication
| Name | Date | Download |
|---|---|---|
| Pismo zdravstvenim radnicima o riziku od nemelanomskog raka kože povezanog s primjenom hidroklorotiazida | 17.10.2018 | Alkaloid, Belupo, Berlin-Chemie Menarini, Boehringer Ingelheim International, Farmal, Genericon, Pharma, Jadran Galenski laboratorij, Krka - farma, Merck, Merck Sharp & Dohme, Novartis, PharmaSwiss, Pliva, Sandoz, sanofi-aventis i Stada |
